Te­va’s an­tipsy­chot­ic as­set pass­es Phase 3 test in schiz­o­phre­nia

Te­va said Wednes­day morn­ing that its schiz­o­phre­nia drug suc­ceed­ed in a Phase 3 tri­al with signs of a dif­fer­en­ti­at­ed safe­ty pro­file ver­sus stan­dard of care.

The Phase 3 SO­LARIS tri­al set TEV-‘749 — a once-month­ly sub­cu­ta­neous ver­sion of atyp­i­cal an­tipsy­chot­ic olan­za­p­ine — against place­bo in adults with schiz­o­phre­nia. The drug, which is be­ing de­vel­oped by Te­va, is de­liv­ered us­ing Med­in­cell’s ex­tend­ed re­lease tech­nol­o­gy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER